Myasthenic ocular weakness

Introduction to Disorders of Ocular Motor Effector Units

When evaluating painless, variable, or progressive ophthalmoplegia and ptosis, the neuro-ophthalmologist must determine whether the underlying failure resides within cranial nerve trunks, the neuromuscular junction (NMJ), or the extraocular muscle fibers themselves. An isolated neurogenic cranial nerve palsy often follows its innervation territory, but combined lesions and mimics complicate localisation. Disorders of the neuromuscular junction (such as Myasthenia Gravis) and primary ocular myopathies (such as Chronic Progressive External Ophthalmoplegia) frequently violate anatomical cranial nerve boundaries.

Mastery of this domain for the EBOD examination requires deep understanding of autoimmune receptor immunology, electrodiagnostic neuromuscular transmission parameters, and mitochondrial genetics, alongside rapid recognition of high-risk systemic complications such as thymomas, cardiac conduction blocks, and respiratory failure.

Myasthenia Gravis (MG)

Epidemiology & Immunopathophysiology

Myasthenia gravis is an acquired, antibody-mediated autoimmune disease directed against functional components of the post-synaptic neuromuscular junction on skeletal muscle fibers. It exhibits a bimodal age distribution: an early peak in the second to fourth decades (predominantly young females, often associated with thymic follicular hyperplasia) and a late peak in the sixth to eighth decades (predominantly males, frequently associated with thymic atrophy or thymoma).

Under normal physiological conditions, an action potential traversing a motor axon depolarizes the presynaptic terminal, triggering voltage-gated calcium influx and quantal exocytosis of acetylcholine (ACh) into the synaptic cleft. ACh binds to post-synaptic nicotinic acetylcholine receptors (AChR) on the folded motor endplate, generating an endplate potential (EPP). Under normal conditions, the EPP substantially exceeds the threshold required to trigger a muscle fiber action potential—a physiological margin known as the safety factor of neuromuscular transmission.

In myasthenia gravis, autoantibodies target key post-synaptic proteins:

1. Anti-Acetylcholine Receptor Antibodies (anti-AChR): Present in 80% to 85% of patients with generalized myasthenia gravis, but detectable in only 50% of patients with purely ocular myasthenia gravis. These antibodies (predominantly IgG1 and IgG3) cause pathology via three synergistic mechanisms:
   • Complement-Mediated Lysis: Activation of the classical complement cascade with deposition of the membrane attack complex (MAC, C5b-9), destroying the secondary synaptic architecture;
   • Receptor Endocytosis (Antigenic Modulation): Divalent antibody cross-linking of AChRs accelerates their internalisation and lysosomal degradation;
   • Functional Blockade: Direct steric hindrance of the acetylcholine-binding site.
   • Consequence: The junctional folds become simplified, synaptic clefts widen, and the density of functional AChRs plummets. With sustained repetitive motor firing, the EPP falls below firing threshold, producing fatiguability.
2. Anti-Muscle-Specific Kinase Antibodies (anti-MuSK): Present in 5% to 8% of generalized MG patients (typically seronegative for anti-AChR). MuSK is a receptor tyrosine kinase essential for agrin-mediated clustering of AChRs during synaptogenesis. MuSK-MG exhibits a marked female predominance, severe bulbar, neck, and respiratory muscle weakness, prominent facial muscle atrophy, and a notoriously poor or adverse response to acetylcholinesterase inhibitors.
3. Anti-Low-Density Lipoprotein Receptor-Related Protein 4 (anti-LRP4): LRP4 acts as the agrin receptor that activates MuSK; autoantibodies to LRP4 account for a subset of double-seronegative MG cases.
4. Anti-Striated Muscle Antibodies (anti-titin, anti-ryanodine): Strongly correlate with the presence of a thymoma in myasthenic patients under the age of 50.

Clinical Presentation: "The Great Impostor"

Myasthenia gravis is famously termed 'The Great Impostor' because it can mimic virtually any non-proptotic ocular motility disturbance, cranial nerve palsy, gaze palsy, or internuclear ophthalmoplegia. However, it exhibits four inviolable clinical hallmarks:

1. characteristic Fluctuating Fatiguability: Symptoms are characteristically variable, fluctuating from hour to hour and day to day. Symptoms are typically milder upon awakening in the morning and deteriorate toward the evening or following prolonged visual tasks.
2. Painless Ptosis & Variable Diplopia: Ocular symptoms represent the initial manifestation in over 50% of patients and develop in $>90\%$ over their disease course. Ptosis may be unilateral, alternating, or bilateral.
3. Sensory function and pain: MG itself does not ordinarily cause sensory loss or painful ophthalmoplegia. Pain or trigeminal dysfunction prompts investigation for another or coexisting disorder rather than exclusion from one finding alone.
4. Pupil assessment: MG does not usually affect iris function. A pupil abnormality needs another explanation but can coexist with MG; it does not rule MG out.

High-Yield Bedside Diagnostic Signs

• Cogan Lid Twitch Sign: The patient directs gaze downward for 10 to 15 seconds, then makes a rapid saccade back to the primary position. The upper eyelid shows a transient, brief overshoot or twitch before settling downward into its ptotic position. This reflects rapid recovery of the levator muscle during downgaze, followed by instantaneous fatigue upon saccadic refixation.
• Curtaining Sign (Enhanced Ptosis): Governed by Hering's law of equal motor innervation. When the examiner manually elevates the more ptotic eyelid, the brainstem central levator subnucleus perceives that less motor effort is needed to maintain open lids. As bilateral central motor drive diminishes, the contralateral, less ptotic eyelid immediately droops downward ('curtains').
• Peek Sign of Orbicularis Oculi Weakness: The patient is asked to close their eyelids gently. Within 30 seconds, the fatigued orbicularis oculi slips open, revealing the underlying sclera ('peeking'). Orbicularis oculi weakness is present in $>80\%$ of ocular MG cases.
• Fatigue Test (Sustained Upgaze): The patient maintains steady fixation on a target in extreme upgaze for 60 seconds; progressive, measurable drooping of one or both eyelids confirms fatiguability.